The estimated Net Worth of Ralph Snyderman is at least $3.62 Milione dollars as of 27 May 2021. Ralph Snyderman owns over 9,500 units of Caredx Inc stock worth over $1,455,458 and over the last 10 years he sold CDNA stock worth over $1,926,255. In addition, he makes $242,217 as Independent Director at Caredx Inc.
Ralph has made over 8 trades of the Caredx Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he sold 9,500 units of CDNA stock worth $761,805 on 27 May 2021.
The largest trade he's ever made was exercising 14,598 units of Caredx Inc stock on 3 March 2020 worth over $54,013. On average, Ralph trades about 850 units every 35 days since 2014. As of 27 May 2021 he still owns at least 51,015 units of Caredx Inc stock.
You can see the complete history of Ralph Snyderman stock trades at the bottom of the page.
Dr. Ralph Snyderman, M.D., is an Independent Director of the Company. Dr. Snyderman has held the position of Chancellor Emeritus and James B. Duke Professor of Medicine at Duke University since July 2004. From January 1989 to June 2004, he served as Chancellor for Health Affairs at the Duke University School of Medicine and was the founding CEO and President of the Duke University Health System. From January 2006 to November 2009, he consulted for New Enterprise Associates, a venture capital firm, as a venture partner. He previously served on the Boards of Directors of The Procter and Gamble Company, Pharmaceutical Product Development, LLC, Targacept, Inc., Trevena, Inc., Press Ganey Associates, Inc., Crescendo Bioscience, Inc., Argos Therapeutics, Inc. and Linus Oncology. He currently serves on the Boards of Directors of iRhythm Technologies, Inc., Liquida Technologies, Inc., Essential Health Solutions, SenGenix, Inc. and Veritas Collaborative. Dr. Snyderman is a member of the Association of American Physicians, where he served as president from 2003 to 2004, the Association of American Medical Colleges, where he served as chair from 2001 to 2002 and the Institute of Medicine and the American Academy of Arts and Sciences. Dr. Snyderman holds a B.S. in Pre-Medical Studies from Washington College, an M.D. from the State University of New York, Downstate Medical Center, and completed an internship and residency in medicine at Duke University.
As the Independent Director of Caredx Inc, the total compensation of Ralph Snyderman at Caredx Inc is $242,217. There are 11 executives at Caredx Inc getting paid more, with Peter Maag having the highest compensation of $8,855,740.
Ralph Snyderman is 80, he's been the Independent Director of Caredx Inc since 2005. There are no older and 16 younger executives at Caredx Inc.
Ralph's mailing address filed with the SEC is C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO, CA, 94103.
Over the last 10 years, insiders at Caredx Inc have traded over $60,271,359 worth of Caredx Inc stock and bought 1,726,634 units worth $9,072,700 . The most active insiders traders include Group Holdings (Sbs) Adviso..., Neil Gagnon e Peter Maag. On average, Caredx Inc executives and independent directors trade stock every 17 days with the average trade being worth of $615,506. The most recent stock trade was executed by Alexander L Johnson on 20 August 2024, trading 61,023 units of CDNA stock currently worth $1,432,820.
caredx: transforming transplant patient care through novel surveillance management solutions caredx, inc. is dedicated to improving the lives of organ transplant patients through non-invasive diagnostics. by combining the latest advances in genomics and bioinformatics technology, with a commitment to generating high quality clinical evidence through trials and registries, caredx is at the forefront of organ transplant surveillance and pre-transplant hla typing solutions. nasdaq:cdna about allosure® allosure is the first and only non-invasive blood test that directly measures allograft injury and identifies the probability of active rejection to better manage kidney transplant patients. allosure is a clinical-grade, proprietary next-generation sequencing (ngs) based test to detect donor-derived cell-free dna (dd-cfdna) in order to identify organ injury in kidney transplant recipients. allosure is analytically validated as a sensitive, specific, and precise measurement of dd-cfdna. allos
Caredx Inc executives and other stock owners filed with the SEC include: